VRI launches allergy Phase II trials
22 October, 2002 by Melissa TrudingerVRI BioMedical has started two Phase II clinical trials in Western Australia and the UK to evaluate the use of its probiotic bacteria for prevention and treatment of allergic disease.
Ellex launches new laser
21 October, 2002 by Graeme O'NeillAdelaide company Ellex Medical Lasers yesterday announced it had a signed a contract with Californian manufacturer Lumenis to produce a compact new photocoagulator laser for retinal surgery, the Laserex LP3532.
Acrux moves into new lab facilities
18 October, 2002 by Melissa TrudingerAcrux has officially opened its new facilities in West Melbourne, kicking off a new phase in the company's growth.
Revealed: bacteria's survival guide
17 October, 2002 by Graeme O'NeillThe bacteria that infect human beings have disarmed almost the entire modern arsenal of antibiotics. Not long after new antibiotics are deployed, resistance appears almost magically.
Agenix gears up to trial blood clot tech
16 October, 2002 by Graeme O'NeillBrisbane biotech company Agenix will begin safety and efficacy trials of its new Thromboview blood-clot imaging technology in healthy human volunteers early next year.
Ellex boosts scientific advisory board
14 October, 2002 by Melissa TrudingerEllex Medical Lasers has boosted its scientific advisory board with the appointment Prof John Marshall, an international expert in ophthalmologic lasers, and Peter Falzon, the former director of business development at US-based laser device company Lumanis.
ResMed takes action against US firm in patent battle
14 October, 2002 by Melissa TrudingerAustralian sleep apnoea devices company ResMed has filed a lawsuit against US-based Respironics, claiming that several Respironics products infringe on ResMed patents.
Benitec, Ozgene team up to build a better rat model
11 October, 2002 by Pete YoungA potentially lucrative bid to provide the drug industry with improved testing capabilities on animal models has been launched by two Australian biotechs.
Cardia restructures with a little help from Big Pharma
11 October, 2002 by Iain ScottMelbourne-based company Cardia Technologies has wrapped its medical biotech projects into a new wholly-owned subsidiary company, Big Pharma Ltd.
Acrux restructures licensing deal
10 October, 2002 by Graeme O'NeillMelbourne pharmaceutical company Acrux has done an IP swap with Soltec Research that will allow both companies to further their development of transdermal and topical therapeutics.
New horizons for pSivida
09 October, 2002 by Pete YoungThe announcement that pSivida's porous silicon technology, BioSilicon, has shown it can perform diagnostic tests when applied as a skin patch opens up new revenue horizons for the Perth biotech.
Sirtex wins humanitarian device award
09 October, 2002 by Melissa TrudingerSydney-based company Sirtex Medical has been awarded the Humanitarian Benefit Device of the Year 2002 for its SIR-Spheres liver cancer treatment by Frost and Sullivan, a US-based market consulting and analyst group.
Clinical Cell Culture turning heads in the US
08 October, 2002 by Pete YoungPerth skin replacement company Clinical Cell Culture (C3) has caught the attention of Nasdaq-listed US artificial skin specialist Integra Life Sciences Corporation.
Devices of industry
04 October, 2002 by Melissa TrudingerOutside the industry, the words 'Australian biotechnology' immediately conjure up three names in particular -- CSL, Cochlear and ResMed. The irony is that none of these companies is strictly a biotechnology company.
BTF boosted by VC funding
03 October, 2002 by Pete YoungA young biotech company founded by two Macquarie University scientists has attracted $2 million in funding from venture capital firm Nanyang Ventures.
